In vivo toxicity assessment of novel antimicrobial peptide derived from lipopolysaccharide- and ©¬-1, 3-glucan-binding protein (LGBP) of the pacific abalone (Haliotis discus hannai)
Eun-Ha Shin, Eun Hee Park, Eun Soo Noh, Young-Ok Kim, Dong-Gyun Kim, Hee Jeong Kong, Jung Youn Park and Bo-Hye Nam
Biotechnology Research Division, National Institute of Fisheries Science, Busan 46083, Korea
Antimicrobial peptides (AMPs) constitute important components of the innate immunity, protecting the host against infections. A synthetic antimicrobial peptide was identified as a possible candidate for the development of a new antibacterial drug. We previously developed novel AMPs derived from a lipopolysaccharide- and ©¬-1, 3-glucan-binding protein (LGBP) of the pacific abalone Haliotis discus hannai (HDH) particularly showing antimicrobial against bacteria and fungi and antitumor activities against several cancer cells.To evaluate in-vivo toxicity of AMPs is an essential step to ensure it safe use in drugs and foods. In the present study, we have investigated to evaluate in-vivo toxicity of HDH-LGBP in mouse when orally administered to both sexes of ICR mice (10 males and 10 females in each group) at dose of 50, 100 and 200 mg/kg/day for 14 days. Individual food/ water consumption and body weight changes were measured daily. The group treated with HDH-LGBP didn¡¯t show any histological change in the kidney and liver. Statistically significant decreases of food consumption, serum creatinine and platelet were found in 200 mg HDH-LGBP-treated groups when compared to their respective controls. It was considered to be caused by stress and peptide gelation. Male and female mice did not show effects body weight, food consumption, organ weights, hematology, serum chemistry, urinalysis or microscopic pathology. Therefore, the no-observed-adverse-effect level (NOAEL) for HDH-LGBP was concluded to be a 200 mg/kg/day. These results corroborate the potential of this novel AMP (HDH-LGBP) as an alternative food preservative or multifunctional drug.
  
36-1-4-23-34.pdf (2.3M), Down : 55, 2020-06-14 15:15:40

   

»ç¹«±¹ & ÆíÁý±¹ : Ãæ³² ¾Æ»ê½Ã ½Åâ¸é ¼øõÇâ·Î 22 ÀÚ¿¬°úÇдëÇР3317È£ / Tel: 041-530-3040 / E-mail : malacol@naver.com